Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

A Phase IIIB, Open-label, Randomized, Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r Based Regimen.

Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).

Inclusion Criteria:

• HIV positive
• LPV/RTV-based HAART for at least 6 months
• HIV-1 RNA less than 50c/mL (confirmed)
• Non-HDL higher than 160 mg/dL
• CD4 of at least 50 cells/mL

Exclusion Criteria:

• Use of lipid-lowering agents